-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Oncternal Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2010 to 2023.
- Oncternal Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$8.46M, a 14.2% increase year-over-year.
- Oncternal Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$34.6M, a 17.1% increase year-over-year.
- Oncternal Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$39.5M, a 10.6% increase from 2022.
- Oncternal Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$44.2M, a 41% decline from 2021.
- Oncternal Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$31.3M, a 81.9% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)